The Microbiome as a
Therapeutic Target in
Inflammatory Bowel Disease.
The DFG Research Unit miTarget 5042 brings together an interdisciplinary group of experts in a coordinated programme to specifically study this single economically important and prototypically complex inflammatory disease.
News Show all
International symposium within the EU project SymbNET on microbiome metabolomics at Kiel University
From November 14-15, 2022, the Collaborative Research Center 1182 “Origin and Function of Metaorganisms” hosted an international symposium at Kiel University as …read more
Patterns of gut microbiome dysbiosis in patients with inflammatory bowel diseases are inconsistent among published studies, probably owing to the heterogeneity of the disease and given the fact that patients enrolled in research studies are often treated and in remission. Therefore, more microbiome studies in “early” (incident) patients that are treatment-naïve and in high-risk individuals are needed. In addition, the microbiome field has to move from association to rather mechanistic studies in order to understand the actual functions and to also prove the associations that serve as hypotheses.
Institute of Clinical Molecular Biology
Prof. Dr. rer. nat. Andre Franke
Fon: +49 (0)431 500-15115
Doctoral qualification programme
Fon: +49 (0)431 500-15113